Here are five things to know:
1. The company’s BRTX-100 is a novel autologous stem cell product to designed to treat degenerative disc disease.
2. In February 2017, BioRestorative received FDA clearance to begin a phase 2 clinical trial of BRTX-100.
3. The phase 2 trial is expected to start in the first quarter of 2019.
4. The company appointed Wayne J. Olan, MD, as clinical director of its regenerative disc/spine program.
5. BioRestorative also developed the ThermoStem program to treat metabolic disorders, including diabetes and obesity.
More articles on biologics:
1st patient enrolled in Cerapedics’ TLIF clinical trial: 5 takeaways
Who are the 10 key players in the $226B spine biologics market?
206 Ortho gets bio-inspired patent: 3 quick notes
